LEO Pharma introduces new operating model to increase competitiveness and support future growth
Ballerup, January 19, 2022 – LEO Pharma today announced the introduction of a new operating model and change program to simplify operations, increase profitability and fund its ambitious growth strategy.
In 2020, LEO Pharma unveiled its strategy towards 2030. The first phase of this strategic transformation process – including the introduction of a new capital and governance structure – was recently completed. Next phase, announced today, is about focusing on core business and operational efficiency, and improving competitiveness and continuous adaptation to the commercial model that best fits the company’s product portfolio and to the evolving needs and preferences of external stakeholders. Through these adjustments, LEO Pharma will be poised for delivering consecutive growth.
“We are at a defining moment in our transformation journey – and in the history of our company even. With our strategy towards 2030, we know that we are well-positioned for a bright future within innovative medical dermatology. To release the full potential, we must now increase profitability and make bold investments in the best and most innovative treatment options for the patients we serve,” said Anders Kronborg, Chief Financial Officer and Acting CEO and President of LEO Pharma, and continued:
“The new operating model we announce today will make a much more simple, agile and efficient LEO Pharma and this is the best way forward for us to ensure a sustainable business model for the future. It will affect employees who have served the company with loyalty and dedication for many years. We will do our utmost to support our colleagues as changes are implemented”.
Simplified setup and focus on core business
To further accelerate the transformation process and increase competitiveness and profitability, LEO Pharma are optimizing its commercial operating model globally and across markets to best fit its product portfolio to the evolving needs and preferences of the external environment.
LEO Pharma’s Global R&D organization will focus the in-house drug discovery on promising small molecule technologies and further increasing productivity to realize the company’s ambition to launch a new innovative asset or enter a new indication every two to three years. Other initiatives include driving efficiencies through outsourcing; further standardization; boosting digitalization as well as centralizing systems, data and analytics. Also, LEO Pharma’s Open Innovation, Regenerative Medicine and the Science & Tech Hubs in Asia and Boston, US, will be closed as a part of the changes announced today.
The changes are expected to affect around 1,000 positions in the global organization over the next two years. Today, the announcement has directly affected 68 people in LEO Pharma’s global organization. Final estimates for headcount impact in all areas of the business are subject to completion of applicable consultation processes.
Poised for growth
Since the launch of the 2030 strategy in 2020, LEO Pharma has progressed on the ambitions of transforming the company into a global leader and top five player in medical dermatology. On this journey, the recent FDA approval of tralokinumab in the US was a major milestone and a turning point in the ability to grow to advance the standard of care for patients, their families and society by bringing innovative treatments to the market. Other key achievements include the efficiency gains and savings already delivered, and successfully expanding sales of the established product portfolio.
By bringing tralokinumab and other innovative treatments successfully to the market and introducing the new operating model, LEO Pharma is poised for delivering consecutive double-digit growth and an EBITDA margin of 25% by 2025 preparing the company for an IPO within a four-to-five year horizon.
Contacts
Media Contact
Henrik Heskjaer
Director, Global External Communications
Tel: +45 3140 6180
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of DKK 10.133 billion. For more information about LEO Pharma, visit www.leo-pharma.com.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab)14.7.2025 13:00:00 CEST | Pressemeddelelse
Partnership will accelerate and broaden access to treatment for more patients with generalized pustular psoriasis (GPP), a rare and devastating skin condition LEO Pharma’s six decades of dermatology expertise and Boehringer’s global track record in bringing SPEVIGO® to over 40 countries will be combined to ensure continuous patient support Boehringer Ingelheim and LEO Pharma will closely cooperate to ensure a smooth transition of all operations
LEO Pharma Announces Positive 16-Week Interim Results for ADHAND Trial for Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis on the Hands who are Candidates for Systemic Therapy9.7.2025 13:00:00 CEST | Pressemeddelelse
ADHAND is a phase 3b placebo-controlled clinical trial evaluating the efficacy and safety of tralokinumab in adult patients living with moderate-to-severe atopic dermatitis on the hands who are candidates for systemic therapy.1 The 16-week interim results of the ADHAND trial met the primary and all key secondary endpoints, showing statistically significant results compared to placebo. This analysis assessed outcomes up to Week 16, but the trial will continue through Week 32, with final results expected by the end of the year.
LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP)3.6.2025 09:00:00 CEST | Pressemeddelelse
The phase 2a proof-of-concept trial will recruit up to 135 adult patients with mild to severe PPP to investigate the efficacy and safety of delgocitinib cream compared to cream vehicle. Delgocitinib cream has been shown to inhibit the activity of all four JAKs,(1,2) making it a potential therapeutic candidate for treating PPP.
LEO Pharma continues to strengthen strategic leadership in medical dermatology with appointment of Helle Hedegaard Juhl as new EVP of Global People & Corporate Affairs2.6.2025 10:00:00 CEST | Pressemeddelelse
A few weeks ago, LEO Pharma announced the appointment of a new EVP for Global People & Corporate Affairs (GPCA) – Helle Hedegaard Juhl will be joining LEO Pharma on July 1. She joins LEO Pharma, alongside recently appointed EVP for International Operations Frederik Kier, to strengthen the company’s leadership and support the next phase of LEO Pharma's strategic journey and transformation
LEO Pharma delivers 9% revenue growth at constant exchange rates and doubles adjusted EBITDA margin to 16%15.5.2025 09:00:00 CEST | Pressemeddelelse
Three-month interim report (Q1) 2025 (Unaudited)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom